12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral methylnaltrexone: Phase III data

A double-blind Phase III trial in 804 patients with chronic, non-cancer pain showed that once-daily 300 and 450 mg oral methylnaltrexone each met the primary endpoint of significantly improving the proportion of patients with a RFBM within 4 hours of treatment each day over 28 days vs. placebo. Additionally, mid- and high-dose oral methylnaltrexone significantly improved the proportion of patients with a RFBM within 4 hours of administration of the first dose vs. placebo. Mid- and high-dose oral methylnaltrexone...

Read the full 371 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >